Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile
In support of the U.S. government’s policy to maintain a stockpile to be able to protect every American from smallpox, Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the...
Emergent BioSolutions to Participate in Series of Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the third quarter of...
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2019
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the second quarter and six months ended June 30,...
Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option valued at $261 million to procure...
Emergent BioSolutions to Release Second Quarter 2019 Financial Results and Conduct a Conference Call on August 1, 2019
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, August 1, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2019, recent...
Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine
mergent BioSolutions Inc. (NYSE:EBS) today announced approval by the U.S. Food and Drug Administration (FDA) of the Prior Approval Supplement (PAS) submitted by the company for its oral cholera...
Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness
Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human...
Emergent BioSolutions to Participate in Series of Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the second quarter of...
Emergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine Vivotif® (Typhoid Vaccine Live Oral Ty21a) in five...
Emergent BioSolutions to Participate in Series of Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the second quarter of...
Emergent BioSolutions Prepares for Initial Shipments of AV7909 Anthrax Vaccine Candidate into the Strategic National Stockpile
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has informed the company that it will begin procuring AV7909 (anthrax...
Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 23, 2019 at 9:00 AM EDT; Webcast Will Be Available
Emergent BioSolutions Inc. (NYSE: EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 23, 2019 beginning at 9:00 AM EDT at the Gaithersburg Marriott Washingtonian...